VNOV — Vitanova Life Sciences Share Price
Last trade - 00:00- $11.51m
- $10.34m
- $2.66m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.21 | ||
| Price to Tang. Book | 6.21 | ||
| Price to Free Cashflow | 13.3 | ||
| Price to Sales | 3.6 | ||
| EV to EBITDA | 8.64 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 64.49% | ||
| Return on Equity | 50.33% | ||
| Operating Margin | 37.44% | ||
Financial Summary
| Year End 30th Apr | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 0.12 | 0.04 | 0.57 | 2.66 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | +156.96 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
VitaNova Life Sciences Corporation, formerly Yijia Group Corp, is a consumer health and business consulting company. The Company's segments include Consulting Service and Dietary Supplement. Its Consulting Service segment provides advisory services in management, business, accounting and finance services. Its Dietary Supplement segment provides dietary supplement products to domestic and international customers. The Company's subsidiary, NutriPeak Trading Corporation, is engaged in the marketing and supply of dietary supplement products.
Directors
- Last Annual
- April 30th, 2025
- Last Interim
- January 31st, 2026
- Incorporated
- January 25th, 2017
- Public Since
- July 12th, 2018
- No. of Shareholders
- 62
- No. of Employees
- 1
- Sector
- Specialty Retailers
- Industry
- Consumer Cyclicals
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 8,337,454
- Address
- 39 E Broadway, Suite 603, NEW YORK, 10002
- Web
- Phone
- +1 9198690279
- Auditors
- Simon & Edward LLP
Upcoming Events for VNOV
Similar to VNOV
Taishengtang
Pink Sheets on Nasdaq
Arion
Pink Sheets on Nasdaq
Avolta AG
Pink Sheets on Nasdaq
bebe stores
Pink Sheets on Nasdaq
Beter Bed Holding BV
Pink Sheets on Nasdaq
FAQ
As of Today at 24:04 UTC, shares in Vitanova Life Sciences are trading at $1.38. This share price information is delayed by 15 minutes.
Shares in Vitanova Life Sciences last closed at $1.38 and the price had moved by +155.56% over the past 365 days. In terms of relative price strength the Vitanova Life Sciences share price has outperformed the S&P500 Index by +100.83% over the past year.
There is no consensus recommendation for this security.
Find out moreVitanova Life Sciences does not currently pay a dividend.
Vitanova Life Sciences does not currently pay a dividend.
Vitanova Life Sciences does not currently pay a dividend.
To buy shares in Vitanova Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.38, shares in Vitanova Life Sciences had a market capitalisation of $11.51m.
Here are the trading details for Vitanova Life Sciences:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: VNOV
Based on an overall assessment of its quality, value and momentum Vitanova Life Sciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vitanova Life Sciences. Over the past six months, its share price has underperformed the S&P500 Index by -74.67%.
As of the last closing price of $1.38, shares in Vitanova Life Sciences were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Vitanova Life Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.38.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Vitanova Life Sciences' directors